3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumour
2
Advanced Solid Tumor
2
Stomach Neoplasms
1
Solid Tumor
1
Simpson-Golabi-Behmel syndrome
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm, Residual
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Tumors
1
Advanced Malignancies
1
Adenocarcinoma Of Esophagus
1
Interventions
Fluorouracil
10
Oxaliplatin
8
Capecitabine
8
pembrolizumab
6
Specimen Handling
6
Nivolumab
6
Leucovorin
6
trastuzumab deruxtecan
5
Magnetic Resonance Spectroscopy
5
Paclitaxel
4
Cisplatin
4
Biopsy
4
fludarabine
3
aldesleukin
3
Trastuzumab
3
Cyclophosphamide
3
zolbetuximab
2
fludarabine phosphate
2
Ramucirumab
2
Folfox protocol
2
Docetaxel
2
zimberelimab
1
zanidatamab
1
ulixertinib
1
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
trametinib
1
toripalimab
1
tislelizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
tislelizumab
×
30 days
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled